CB Scientific, Inc. Enters Beta Testing of Its Updated Proprietary My-Cam Cardiac Event Monitor
News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.
Updates to provide device enhancements while maintaining the innovative core functionality of the CBSC’s state-of-the-art cardiac event monitor
ESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK: CBSC) (“CBSC” or the “Company”) announced today that the Company has entered beta testing for its updated My-Cam cardiac event monitoring device. The updated design offers improved power consumption, improved shielding of lead wires, improved signal quality, and more cost effective parts supply while maintaining its core functionality of being an advanced automatic trigger device.
As demand for the My-Cam device continues to grow across all of CB Scientific’s subsidiaries and partners, CBSC’s commitment to the manufacturing process, both nationally and internationally, will ensure that the company will be successful. able to meet customer demand throughout the current supply chain crisis and beyond. . The company expects that once beta testing is successful, it will move on to pre-production testing (also known as user acceptance testing) in the coming weeks.
As new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants and the markets informed audiences.
About CB Scientific, Inc.
CB Scientific, Inc., through its national and international subsidiaries, provides innovative products and services in the field of ambulatory non-invasive cardiac monitoring. Our FDA and CE approved ECG devices, cloud-based interactive acquisition software, and smartphone apps for iOS and Android platforms improve compliance of patients at risk for abnormal heart rhythms, along with more information accurate for physicians.
Company details :
Telephone: (888) 225-0870
Email: General inquiries: [email protected]
Investor inquiries: Robert Hesse – [email protected]
Follow the CCNR: Twitter, Facebook, Instagram, LinkedIn, YouTube and Newsletter
This information disclosure may contain covered forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate, among other things, to the plans and timing for the introduction or improvement of our services and products, statements on future market conditions, supply and demand conditions and other expectations, intentions and plans contained in this press release which are not historical facts and involve risks and uncertainties. Our expectations for future revenues depend on our ability to develop and deliver products and services that we cannot produce today and that meet defined specifications. When used in this press release, the words “plan”, “expect”, “believe” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties including, but not limited to, technological changes and changes in pervasive markets. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this press release that are not historical facts may be considered as forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from those projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain funding and regulatory and shareholder approval for planned actions.
THE SOURCE: CB Scientific, Inc.
See the source version on accesswire.com: